Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction.
Moriarty
P M
PM
Lipid, Atherosclerosis, and Metabolic Clinic, University of Kansas Medical Center, Kansas City 66160-7374, USA. pmoriart@kumc.edu
D001161:Arteriosclerosis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008055:Lipids